What is the 13F Pro Quality Score for ARMP?

13F Pro ranks Armata Pharmaceuticals, Inc. (ARMP) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ARMP's current score at https://13fpro.ai/research/ARMP (free sign-up required for the full ranking).

Where does 13F Pro source ARMP data?

All Armata Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Armata Pharmaceuticals, Inc. files with the SEC under CIK 921114. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ARMP in?

Armata Pharmaceuticals, Inc. (ARMP) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ARMP research updated on 13F Pro?

ARMP's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Armata Pharmaceuticals, Inc.(ARMP)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 921114 ARMP stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ARMP Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Armata Pharmaceuticals, Inc. (ARMP), a Healthcare sector company. ARMP is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Armata Pharmaceuticals, Inc. reports net income of $-115.3M, free cash flow of $-5.8M. Top institutional holders of ARMP by reported 13-F value include Madison Asset Management,, VANGUARD CAPITAL MANAGEMENT, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. ARMP trades on the NYSE exchange and files with the SEC under CIK 921114. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARMP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Armata Pharmaceuticals, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-115.3M

Free Cash Flow

Q1 2026

$-5.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+72.6% YoY

$-18.9MFY 2024

FY21 $-23.2MFY22 $-36.9MFY23 $-69.0MFY24 $-18.9M

Operating Income

-3.8% YoY

$-42.4MFY 2024

FY21 $-23.8MFY22 $-36.9MFY23 $-40.9MFY24 $-42.4M

EPS (Diluted)

+53.4% YoY

$-0.89FY 2024

FY21 $-0.96FY22 $-1.08FY23 $-1.91FY24 $-0.89

Total Assets

-12.1% YoY

$86.4MFY 2024

FY21 $69.8MFY22 $95.8MFY23 $98.4MFY24 $86.4M

Op. Cash Flow

+20.8% YoY

$-37.6MFY 2024

FY21 $-23.6MFY22 $-32.5MFY23 $-47.4MFY24 $-37.6M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Net Income	$-18.9M +72.6%	$-69.0M -87.0%	$-36.9M -59.4%	$-23.2M -4.4%	$-22.2M -13.9%	$-19.5M
Operating Income	$-42.4M -3.8%	$-40.9M -10.7%	$-36.9M -55.1%	$-23.8M -10.4%	$-21.6M -9.3%	$-19.8M
EPS (Diluted)	$-0.89 +53.4%	$-1.91 -76.9%	$-1.08 -12.5%	$-0.96 +28.9%	$-1.35 +47.1%	$-2.55
Total Assets	$86.4M -12.1%	$98.4M +2.6%	$95.8M +37.4%	$69.8M +76.6%	$39.5M +55.3%	$25.5M
Operating Cash Flow	$-37.6M +20.8%	$-47.4M -46.0%	$-32.5M -37.8%	$-23.6M -29.0%	$-18.3M -17.3%	$-15.6M

AI Insight: ARMP Financial Trends

Armata is burning through equity at an accelerating rate, with Q1 2026 equity deficit reaching -$312M amid persistent operating losses and minimal cash generation.

• Operating income losses narrowed from -$14M in Q4 2025 to -$9M in Q1 2026, showing modest operational improvement.

• Operating cash flow deteriorated only marginally from -$7M to -$6M sequentially, but cumulative 8-quarter burn totals -$63M.

• Equity deficit expanded 42% in one quarter: -$219M (Q4 2025) to -$312M (Q1 2026), signaling acute balance-sheet stress.

⚠ Net loss of -$115M in Q1 2026 follows -$124M in Q4 2025; consecutive nine-figure quarterly losses unsustainable without capital infusion.

⚠ No revenue reported across all eight quarters; company remains pre-commercial with no visible monetization path.

AI Insight: ARMP Ratio Trends

Insufficient operational and profitability data to assess trends; only ROA available and deteriorated sharply through Q2 2025.

• ROA collapsed from 12.0% in Q4 2024 to -80.7% in Q2 2025, indicating severe earnings deterioration.

⚠ No financial metrics reported for Q3 2025, Q4 2025, or Q1 2026 TTM; lack of visibility into recent performance.

Get alerted when ARMP's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Armata Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ARMP

Madison Asset Management, LLC
$21.6M2,107,675 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.7M366,028 sh
MILLENNIUM MANAGEMENT LLC
$2.6M257,992 sh
683 Capital Management, LLC
$1.4M137,000 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.2M114,555 sh
EDGEWOOD MANAGEMENT LLC
$1.0M100,000 sh
Dauntless Investment Group, LLC
$927.5K90,580 sh
SEI INVESTMENTS CO
$759.7K74,192 sh
VANGUARD FIDUCIARY TRUST CO
$694.9K67,864 sh
BlackRock, Inc.
$666.1K65,050 sh

Fund	Value	Shares
Madison Asset Management, LLC	$21.6M	2,107,675
VANGUARD CAPITAL MANAGEMENT LLC	$3.7M	366,028
MILLENNIUM MANAGEMENT LLC	$2.6M	257,992
683 Capital Management, LLC	$1.4M	137,000
GEODE CAPITAL MANAGEMENT, LLC	$1.2M	114,555
EDGEWOOD MANAGEMENT LLC	$1.0M	100,000
Dauntless Investment Group, LLC	$927.5K	90,580
SEI INVESTMENTS CO	$759.7K	74,192
VANGUARD FIDUCIARY TRUST CO	$694.9K	67,864
BlackRock, Inc.	$666.1K	65,050

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ARMP on your watchlist

Track score changes the day Armata Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ARMP a good stock to buy?

13F Pro's AI-powered analysis of Armata Pharmaceuticals, Inc. (ARMP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ARMP are available on the ARMP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ARMP?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ARMP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Armata Pharmaceuticals, Inc.'s investment landscape.